Virtual screening for kinase targets

被引:57
作者
Muegge, I
Enyedy, IJ
机构
[1] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA
[2] Bayer Res Ctr, West Haven, CT 06516 USA
关键词
database searching; computational chemistry; rational drug design; lead identification; ATP binding pocket;
D O I
10.2174/0929867043455684
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Kinases have become a major area of drug discovery and structure-based design. Hundreds of 3D structures for more than thirty different kinases are available to the public. High structural and sequence homology within the kinase gene family makes the remaining kinases ideal targets for homology modeling and virtual screening. Somewhat surprisingly, however, the number of publications about virtual screening of kinases is very low. Therefore, rather than reviewing the field of virtual screening for kinases, we attempt here a hybrid approach of presenting what is known and common practice together with new studies on CDK2 and SRC kinase. To illustrate the challenges and pitfalls of virtual screening for kinase targets we focus on the question of how ranking is influenced by the database screened, the docking scheme, the scoring function, the activity of the compounds used for testing, and small changes in the binding pocket. In addition, a case study of finding irreversible inhibitors of ErbB2 through in silico screening is presented.
引用
收藏
页码:693 / 707
页数:15
相关论文
共 107 条
[71]   A scoring scheme for discriminating between drugs and nondrugs [J].
Sadowski, J ;
Kubinyi, H .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (18) :3325-3329
[72]   EVALUATION OF COMPARATIVE PROTEIN MODELING BY MODELER [J].
SALI, A ;
POTTERTON, L ;
YUAN, F ;
VANVLIJMEN, H ;
KARPLUS, M .
PROTEINS-STRUCTURE FUNCTION AND GENETICS, 1995, 23 (03) :318-326
[73]   MODELING MUTATIONS AND HOMOLOGOUS PROTEINS [J].
SALI, A .
CURRENT OPINION IN BIOTECHNOLOGY, 1995, 6 (04) :437-451
[74]   Rational therapeutic intervention in cancer: kinases as drug targets [J].
Sawyers, CL .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 2002, 12 (01) :111-115
[75]   Structural biology in drug design: selective protein kinase inhibitors [J].
Scapin, G .
DRUG DISCOVERY TODAY, 2002, 7 (11) :601-611
[76]   Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase [J].
Schindler, T ;
Bornmann, W ;
Pellicena, P ;
Miller, WT ;
Clarkson, B ;
Kuriyan, J .
SCIENCE, 2000, 289 (5486) :1938-1942
[77]  
Schnecke V, 1998, PROTEINS, V33, P74, DOI 10.1002/(SICI)1097-0134(19981001)33:1<74::AID-PROT7>3.3.CO
[78]  
2-4
[79]  
*SCHROED INC, GLIDE
[80]   Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases [J].
Singh, J ;
Dobrusin, EM ;
Fry, DW ;
Haske, T ;
Whitty, A ;
McNamara, DJ .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (07) :1130-1135